[go: up one dir, main page]

AR112602A1 - ANTICUERPOS ANTI-TrkB - Google Patents

ANTICUERPOS ANTI-TrkB

Info

Publication number
AR112602A1
AR112602A1 ARP180101558A AR112602A1 AR 112602 A1 AR112602 A1 AR 112602A1 AR P180101558 A ARP180101558 A AR P180101558A AR 112602 A1 AR112602 A1 AR 112602A1
Authority
AR
Argentina
Prior art keywords
trkb antibodies
trkb
antibodies
diagnostic
vector
Prior art date
Application number
Other languages
English (en)
Inventor
Haiguang Xiao
Vladimir Voynov
Sathyadevi Venkataramani
Heiko Friedrich Stahl
Sanjaya Singh
Holger Rosenbrock
Sarah Low
Cynthia Hess Kenny
Lore Florin
Michael Dziegelewski
Peter Michael Benz
Sebastian Bandholtz
Remko Alexander Bakker
Rolf Herrmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR112602A1 publication Critical patent/AR112602A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Anticuerpos agonistas anti-TrkB y métodos terapéuticos y de diagnóstico y composiciones para su uso. Vector y célula huésped.
ARP180101558 2017-06-09 2018-06-08 ANTICUERPOS ANTI-TrkB AR112602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09

Publications (1)

Publication Number Publication Date
AR112602A1 true AR112602A1 (es) 2019-11-20

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101558 AR112602A1 (es) 2017-06-09 2018-06-08 ANTICUERPOS ANTI-TrkB

Country Status (22)

Country Link
US (3) US10793634B2 (es)
EP (1) EP3635004A1 (es)
JP (2) JP7267208B2 (es)
KR (1) KR20200017421A (es)
CN (1) CN110719916B (es)
AR (1) AR112602A1 (es)
AU (1) AU2018279184B2 (es)
BR (1) BR112019023742A2 (es)
CA (1) CA3063965A1 (es)
CL (1) CL2019003557A1 (es)
CO (1) CO2019013718A2 (es)
EA (1) EA201992883A1 (es)
IL (1) IL271067B2 (es)
MA (1) MA49257A (es)
MX (1) MX2019014714A (es)
MY (1) MY202315A (es)
PE (1) PE20200173A1 (es)
PH (1) PH12019502694A1 (es)
SG (1) SG11201911814UA (es)
TW (2) TWI808086B (es)
UA (1) UA127967C2 (es)
WO (1) WO2018224630A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
PH12022551101A1 (en) 2019-11-11 2023-11-13 Boehringer Ingelheim Int Npy2 receptor agonists
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
EP4232474A1 (en) * 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
WO2025062271A1 (en) * 2023-09-19 2025-03-27 Signorile Pietro Giulio Antibodies against endometriosis
CN119841947A (zh) * 2024-12-17 2025-04-18 河南农业大学 十二指肠贾第虫cwp2蛋白的单克隆抗体及配对单克隆抗体及应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MX2007015292A (es) 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
KR20090088896A (ko) * 2006-11-09 2009-08-20 아이알엠 엘엘씨 효현제 ｔｒｋｂ 항체 및 그의 용도
MX2009006794A (es) 2006-12-20 2009-07-02 Rinat Neuroscience Corp Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
JP2011501760A (ja) 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
CN102015769B (zh) * 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
EA021284B1 (ru) * 2008-02-04 2015-05-29 Лей Лайн Дженомикс С.П.А. Антитела и их производные
CA2732266A1 (en) * 2008-07-28 2010-02-04 Emory University Treating various disorders using trkb agonists
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
CN103108633B (zh) * 2010-06-09 2016-01-27 爱默蕾大学 TrkB激动剂及其用途
WO2012027821A1 (en) 2010-09-03 2012-03-08 The Royal Institution For The Advancement Of Learning / Mcgill University A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
TW201730206A (zh) 2015-11-17 2017-09-01 葛蘭素史克智慧財產發展有限公司 用於治療神經及其他疾病之結合激動劑
US11066474B2 (en) 2017-11-30 2021-07-20 Regeneron Pharmaceuticals, Inc. Anti-TrkB monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
PH12019502694A1 (en) 2020-07-13
PE20200173A1 (es) 2020-01-24
MY202315A (en) 2024-04-23
CN110719916B (zh) 2024-05-31
TW202342100A (zh) 2023-11-01
MX2019014714A (es) 2020-02-07
BR112019023742A2 (pt) 2020-06-09
AU2018279184A1 (en) 2019-11-21
US11866501B2 (en) 2024-01-09
TWI808086B (zh) 2023-07-11
CO2019013718A2 (es) 2020-01-17
IL271067B2 (en) 2024-06-01
WO2018224630A1 (en) 2018-12-13
IL271067B1 (en) 2024-02-01
CL2019003557A1 (es) 2020-05-04
TW201920271A (zh) 2019-06-01
JP2020522270A (ja) 2020-07-30
JP7267208B2 (ja) 2023-05-01
JP2023093621A (ja) 2023-07-04
US20240101689A1 (en) 2024-03-28
MA49257A (fr) 2020-04-15
IL271067A (en) 2020-01-30
US20200399378A1 (en) 2020-12-24
CA3063965A1 (en) 2018-12-13
NZ758651A (en) 2024-11-29
AU2018279184B2 (en) 2024-08-01
UA127967C2 (uk) 2024-02-28
US20180355046A1 (en) 2018-12-13
EA201992883A1 (ru) 2020-05-08
CN110719916A (zh) 2020-01-21
EP3635004A1 (en) 2020-04-15
KR20200017421A (ko) 2020-02-18
US10793634B2 (en) 2020-10-06
JP7505084B2 (ja) 2024-06-24
SG11201911814UA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
BR112019012342A2 (pt) anticorpos il-11
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
BR112017004141B8 (pt) Agente de imagemamento e seu uso
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
PT3200582T (pt) Composições, kits e métodos para induzir citorresistência adquirida com utilização de indutores de proteínas de stress
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.